These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36117921)

  • 1. Trends in clinical characteristics and factors associated with initial prescription of SGLT2 inhibitors in Japanese patients with type 2 diabetes mellitus.
    Takahashi H; Suganuma Y; Ohno T; Nishimura R
    Diabetol Int; 2022 Oct; 13(4):606-614. PubMed ID: 36117921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease.
    Baek JH; Yang YS; Ko SH; Han KD; Kim JH; Moon MK; Park JS; Lee BW; Oh TJ; Chon S; Choi JH; Hur KY
    Diabetes Metab J; 2022 Sep; 46(5):701-712. PubMed ID: 35654585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry.
    Becher PM; Schrage B; Ferrannini G; Benson L; Butler J; Carrero JJ; Cosentino F; Dahlström U; Mellbin L; Rosano GMC; Sinagra G; Stolfo D; Lund LH; Savarese G
    Eur J Heart Fail; 2021 Jun; 23(6):1012-1022. PubMed ID: 33599357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study.
    Jeong SJ; Lee SE; Shin DH; Park IB; Lee HS; Kim KA
    BMC Nephrol; 2021 May; 22(1):177. PubMed ID: 33990175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do Glucagonlike Peptide-1 Receptor Agonist and Sodium-glucose Co-transporter 2 Inhibitor Prescriptions in Germany Reflect Recommendations for Type 2 Diabetes with Cardiovascular Disease of the ADA/EASD Consensus Report?
    Barth SD; Kostev K; Krensel M; Mathey E; Rathmann W
    Exp Clin Endocrinol Diabetes; 2023 Mar; 131(3):153-161. PubMed ID: 35981560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY
    Prázný M; Suplotova L; Gumprecht J; Kamenov Z; Fülöp T; Medvedchikov A; Rosenzweig D; Aleksandric M
    Cardiovasc Diabetol; 2022 Oct; 21(1):203. PubMed ID: 36209118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Underprescription of SGLT2i and GLP-1 RA: CAREPRO-T2D (Cardiorenal Protection in Type 2 Diabetes) Cross-Sectional Study.
    Simões de Carvalho F; de Brito Marques F; Lopes AE; Lima Ferreira J; Príncipe RM
    Cureus; 2023 Jan; 15(1):e33509. PubMed ID: 36628395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Cardiovascular Outcomes in Patients with Diabetes Mellitus and Heart Failure.
    Hofer F; Kazem N; Richter B; Sulzgruber P; Schweitzer R; Pailer U; Hammer A; Koller L; Hengstenberg C; Niessner A
    Cardiovasc Drugs Ther; 2022 Jun; 36(3):497-504. PubMed ID: 34342791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the initial decline in estimated glomerular filtration rate on the risk of new-onset atrial fibrillation and adverse cardiovascular and renal events in patients with type 2 diabetes treated with sodium-glucose co-transporter-2 inhibitors.
    Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
    Diabetes Obes Metab; 2021 Sep; 23(9):2077-2089. PubMed ID: 34047459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
    Lin DS; Yu AL; Lo HY; Lien CW; Lee JK; Chiang FT; Tu YK
    Eur J Endocrinol; 2023 Jul; 189(1):S17-S25. PubMed ID: 37474112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2i as fourth-line therapy and risk of mortality, end-stage renal diseases and cardiovascular diseases in patients with type 2 diabetes mellitus.
    Wong CKH; Tang EHM; Man KKC; Chan EWY; Wong ICK; Lam CLK
    Diabetes Metab; 2021 Jul; 47(4):101196. PubMed ID: 33039672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns and Patients' Characteristics Associated With Use of Sodium-Glucose Cotransporter-2 Inhibitors Among Adults With Type 2 Diabetes: A Population-based Cohort Study.
    Campbell DB; Campbell DJT; Au F; Beall RF; Ronksley PE; Chew DS; Ogundeji Y; Manns BJ; Hemmelgarn BR; Tonelli M; Quinn AE
    Can J Diabetes; 2023 Feb; 47(1):58-65.e2. PubMed ID: 36184371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States.
    Zhao JZ; Weinhandl ED; Carlson AM; St Peter WL
    Kidney Med; 2023 Jan; 5(1):100564. PubMed ID: 36593878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.
    Banerjee M; Maisnam I; Pal R; Mukhopadhyay S
    Eur Heart J; 2023 Oct; 44(37):3686-3696. PubMed ID: 37605637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial Acute Decline in Estimated Glomerular Filtration Rate After Sodium-Glucose Cotransporter-2 Inhibitor in Patients With Chronic Kidney Disease.
    Sugiyama S; Yoshida A; Hieshima K; Kurinami N; Jinnouchi K; Tanaka M; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T; Jinnouchi H
    J Clin Med Res; 2020 Nov; 12(11):724-733. PubMed ID: 33224374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
    Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
    Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
    Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of SGLT2 inhibitors on old age patients with heart failure and chronic kidney disease.
    Amioka M; Sanada R; Matsumura H; Kinoshita H; Sairaku A; Morishima N; Nakano Y
    Int J Cardiol; 2023 Jan; 370():294-299. PubMed ID: 36174820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescription patterns of diabetes medications influencing clinical outcomes of heart failure patients with reduced ejection fraction.
    Chang HY; Su YW; Feng AN; Fong MC; Huang KC; Chong E; Chen KC; Yin WH
    ESC Heart Fail; 2020 Apr; 7(2):604-615. PubMed ID: 31995274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center.
    Thewjitcharoen Y; Yenseung N; Malidaeng A; Nakasatien S; Chotwanvirat P; Krittiyawong S; Wanothayaroj E; Himathongkam T
    Diabetol Metab Syndr; 2017; 9():96. PubMed ID: 29213337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.